Plfr inhibitors are a class of chemical compounds that specifically target and inhibit the activity of Plfr (Prl7d1), which stands for prolactin family 7, subfamily d, member 1. Prl7d1 is a protein that belongs to the prolactin family, which is known to play roles in various physiological processes, particularly in reproduction, immune modulation, and tissue growth. While the detailed function of Prl7d1 remains less understood compared to other prolactin family members, it is believed to have important regulatory roles in cellular signaling and interactions. Plfr inhibitors work by blocking the activity of this protein, which allows researchers to study its precise biological function and its impact on various cellular pathways.
The use of Plfr inhibitors has opened up opportunities for exploring how Prl7d1 contributes to cellular growth, communication, and regulation in specific tissues. By inhibiting Plfr, researchers can observe changes in cellular behavior, such as alterations in cell proliferation, differentiation, and signaling dynamics. This helps to map out the roles of Prl7d1 in various biological contexts, particularly in understanding how this protein influences intracellular signaling networks and interactions with other members of the prolactin family. Additionally, Plfr inhibitors are valuable tools for investigating how disruptions in Prl7d1 function affect broader physiological processes, providing insights into its importance in maintaining cellular balance and its contribution to complex molecular systems in the body.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $272.00 | 18 | |
Tamoxifen can inhibit various hormone-related pathways and might affect the expression of Plfr in mammary tissues. | ||||||
ICI 182,780 | 129453-61-8 | sc-203435 sc-203435A | 1 mg 10 mg | $83.00 $187.00 | 34 | |
Acts as an estrogen receptor antagonist and might influence the expression of hormone-responsive genes, including Plfr. | ||||||
Mifepristone | 84371-65-3 | sc-203134 | 100 mg | $61.00 | 17 | |
As a glucocorticoid receptor antagonist, RU486 might indirectly influence Plfr expression in tissues where both receptors are co-expressed. | ||||||
Letrozole | 112809-51-5 | sc-204791 sc-204791A | 25 mg 50 mg | $87.00 $147.00 | 5 | |
Inhibits estrogen synthesis and may downregulate Plfr expression in estrogen-responsive tissues. | ||||||
Anastrozole | 120511-73-1 | sc-217647 | 10 mg | $92.00 | 1 | |
Another aromatase inhibitor that suppresses estrogen production and might reduce Plfr expression. | ||||||
Exemestane | 107868-30-4 | sc-203045 sc-203045A | 25 mg 100 mg | $134.00 $411.00 | ||
By inhibiting aromatase, it reduces estrogen levels and might indirectly reduce Plfr expression. | ||||||
Toremifene | 89778-26-7 | sc-205868 sc-205868A | 500 mg 1 g | $85.00 $129.00 | 1 | |
This selective estrogen receptor modulator might influence Plfr expression in mammary tissues. | ||||||
Raloxifene | 84449-90-1 | sc-476458 | 1 g | $802.00 | 3 | |
As an estrogen receptor modulator, it might affect the expression of Plfr in hormone-responsive tissues. | ||||||